DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



RCT Iron Supplementation and Malaria Chemoprophylaxis for Prevention of Severe Anemia and Malaria in Tanzanian Infants

Information source: Hospital Clinic of Barcelona
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Malaria; Anemia

Intervention: Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone) (Drug); iron (2 mg/kg/daily) (Drug)

Phase: N/A

Status: Terminated

Sponsored by: Hospital Clinic of Barcelona

Official(s) and/or principal investigator(s):
Clara Menendez, MD, PhD, Principal Investigator, Affiliation: Centre for International Health, Hospital Clinic / Universitat Barcelona

Summary

The purpose of this trial is to evaluate the efficacy of weekly iron supplementation and the efficacy of malaria chemoprophylaxis from 2 to 12 months of age in infants living in an area of intense and perennial malaria transmission

Clinical Details

Official title: The Prevention of Anaemia and Malaria in Infants in an Area of Intense and Perennial Malaria Transmission

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention

Primary outcome:

Clinical Malaria

Severe Anemia (PCV < 25%)

Secondary outcome:

Clinical Malaria

Severe Anemia (PCV < 25%)

Outpatient visits

Hospital Admissions

Severe malaria

Detailed description: 411 Tanzanian infants were randomly assigned to receive weekly malaria prophylaxis with Deltaprimâ„¢ (3. 125 mg pyrimethamine plus 25 mg dapsone) or placebo from ages 2-12 months. Children were followed-up until age 4 years. Uncomplicated febrile malaria, severe malaria and anaemia morbidity were assessed through hospital-based passive surveillance.

Eligibility

Minimum age: N/A. Maximum age: 1 Day. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Born in San Francis Designated District Hospital of Ifakara

Exclusion Criteria:

- Obvious severe congenital malformation such as: spina bifida, hydrocephalus or

anencepahlus

- Twins

- Birth weight < 1,5 kg

- Clinical signs of cerebral asphyxia

- Clinical signs of neonatal or congenital infection

- Mother unreliable (deaf, mentally handicapped)

Locations and Contacts

Ifakara Centre, Ifakara, Tanzania
Additional Information

Starting date: February 1995
Last updated: July 5, 2007

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017